Skip to Content

BCMA Targeted Therapies, 2017-2030: Even Though Big Pharmaceutical Companies Dominate the Current Space, Several Start-Ups/Small Companies Have Emerged – Research and Markets

by April 13, 2017 General

DUBLIN, Apr. 13, 2017 /PRNewswire/ —

Research and Markets has announced the addition of the “BCMA Targeted Therapies, 2017-2030” report to their offering.

Research and Markets Logo

The “BCMA Targeted Therapies, 2017-2030” report features an extensive study on the current market landscape of B-cell maturation antigen (BCMA) targeted therapies and offers a comprehensive discussion on the future potential of this market. With no commercial products, the market is still in its infancy.However, industry experts have pinned significant hopes on the novel technologies being developed by start-ups/small companies and the research being conducted at academic institutes.

B-cell maturation antigen (BCMA), an important biomarker of the B-cells, has emerged as a promising therapeutic target for the treatment of multiple myeloma and other hematological malignancies. The antigen is universally expressed on the surface of multiple myeloma cells. The research focus shifted towards BCMA targeted therapies in 2004, when the role of BCMA was first indicated in the progression of multiple myeloma. It is the second most common type (13%) of all hematological malignancies.

Results of preclinical and clinical studies have demonstrated the potential benefits of this class of therapies; the major highlight being their attractive safety profile. As more molecules undergo clinical validation and eventually get commercialized, we believe the overall interest will continue to rise. In fact, our promising outlook is backed by a strong belief that this novel class of therapies is likely to cater to the current unmet need where the existing treatment modalities are not efficient. The upside could be higher; however, it depends on a favorable market environment, reimbursement practices and regulatory regimes.

The prime target indication of these novel molecules is B-cell malignancies, specifically multiple myeloma. BCMA-specific therapies are anticipated to emerge as viable treatment options for such indications. Post initial research on such therapies, many players have entered into collaborations with other stakeholders to fund the clinical and commercial development of their products. Some clinical stage products that have emerged out of such collaborations include bb2121 (bluebird bio/Celgene) and BCMA-CART (Novartis/Abramson Cancer Center of the University of Pennsylvania).

The pipeline currently comprises of 23 molecules that are under development for the treatment of a variety of B-cell malignancies. One of the key objectives of this report was to understand the evolution of the current market and to quantify the opportunities laid down by the innovative BCMA targeted programs of both small and big pharma companies.

Key Topics Covered:

1.1. Chapter Overview
1.2. Research Methodology
1.3. Chapter Outlines


3.1. Chapter Overview
3.2. The B-Cell Maturation Antigen
3.3. Drug Classes for BCMA Targeted Therapies
3.4. BCMA Targeted Therapies and Research Landscape
3.5. Emergence of BCMA as a Therapeutic Target for the Treatment of Multiple Myeloma
3.6. BCMA Related Targets: A Case Study

4.1. Chapter Overview
4.2. Development Pipeline
4.3. Distribution by Phase of Development
4.4. Distribution by Type of Molecule
4.5. Distribution by Type of Developer
4.6. Distribution by Indication
4.7. Geographical Landscape
4.8. Developer Landscape

5.1. Chapter Overview
5.2. bb2121 (bluebird bio, Celgene)
5.3. CART-BCMA (Novartis, Abramson Cancer Center of the University of Pennsylvania)
5.4. Anti-BCMA CAR-T (National Cancer Institute)
5.5. Anti-BCMA CAR-T (Southwest Hospital, China)
5.6. GSK2857916/J6M0-mcMMAF (GSK, Seattle Genetics)
5.7. AMG 420/BI 836909 (Amgen, Boehringer Ingelheim)
5.8. BCMA Targeted Therapies: Clinical Development Analysis

6.1. Chapter Overview
6.2. BCMA Targeted Therapies: List of Funding Instances
6.3. Funding Instances: Distribution by Year
6.4. Funding Instances: Distribution by Type of Model
6.5. Leading Players: Distribution by Number of Funding Instances
6.6. Most Active Venture Capital Firms/Investors

7.1. Chapter Overview
7.2. Partnership Models/Agreements
7.3. BCMA Targeted Therapies: Recent Collaborations
7.4. Recent Collaborations: Distribution by Year
7.5. Recent Collaborations: Distribution by Type of Model
7.6. Recent Collaborations: Distribution by Type of Molecule
7.7. Recent Collaborations: Most Active Companies

8.1. Chapter Overview
8.2. Scope and Limitation
8.3. Forecast Methodology
8.4. Overall BCMA Targeted Therapeutics Market
8.5. BCMA Targeted Therapeutics Market: Drug Specific Forecasts

9.1. BCMA has Emerged as a Potential Antigen for the Treatment of Multiple Myeloma
9.2. Led by a Number of Technological Advances, CAR- T Therapies are the Current Flag-Bearer
9.3. Even Though Big Pharmaceutical Companies Dominate the Current Space, Several Start-Ups/Small Companies Have Emerged
9.4. Growing Partnerships and Venture Capital Support are Indicative of the Future Potential
9.5. Once Approved, BCMA Targeted Therapies are Poised to Achieve an Accelerated Growth



  • ADC Therapeutics
  • ARCH Venture Partners
  • AbbVie
  • Abramson Cancer Center of the University of Pennsylvania
  • Acorn Campus Ventures
  • Adimab
  • Aduro Biotech
  • Advanced Technology Ventures
  • Aeris Capital
  • Affimed
  • Alaska Permanent Fund
  • Alexo Therapeutics
  • Alta Partners
  • Amgen
  • Aquilo Capital Management
  • Atlante Biotech
  • Autolus
  • BankInvest Biomedical Venture
  • Baylor College of Medicine
  • Bezos Expeditions
  • BioMedInvest
  • Bluebird bio
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • California Institute for Biomedical Research
  • California Institute for Regenerative Medicine
  • Cancer Institute, University College London
  • Celgene
  • Cellectis
  • Commercial Street Capital
  • Cowen and Company
  • Credit Suisse Securities
  • Dana-Farber Cancer Institute
  • Deerfield Partners
  • Diamond Capital Company
  • Discover Growth Fund
  • Domain Associates
  • Easton Capital
  • Edmond de Rothschild Investment Partners
  • EngMab
  • Eureka Therapeutics
  • FirstVentury Equity
  • Five Prime Therapeutics
  • Forbion Capital Partners
  • French Muscular Dystrophy Association (AFM)
  • Genzyme Ventures
  • GlaxoSmithKline (GSK)
  • Harbinger Venture Capital
  • Health Canada
  • Healthcap Venture Capital
  • Heidelberg Pharma
  • Hercules Technology Growth Capital
  • Idinvest Partners
  • Immune Pharmaceuticals
  • Institute of Molecular and Cell Biology
  • JP Morgan Bay Area Equity Fund
  • Janssen Biotech
  • Janssen Pharmaceuticals
  • Jefferies
  • Johnson & Johnson
  • Juno Therapeutics
  • Kite Pharma
  • Kleiner Perkins Caufield & Byers
  • Life Sciences Partners
  • Majuven
  • Malin Corporation
  • Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)
  • McMaster University
  • MedImmune
  • Memorial Sloan Kettering Cancer Center (MSKCC)
  • Merlin Nexus
  • Methodist Hospital, Houston
  • Micromet
  • Millennium Pharmaceuticals
  • National Cancer Institute (NCI)
  • Novartis
  • Novartis Institute for Biomedical Research
  • Novartis-Penn Center for Advanced Cellular Therapeutics
  • Novo Nordisk
  • Odyssee Venture
  • Onyx Pharmaceuticals
  • OrbiMed
  • Pfizer
  • Pontifax
  • Poseida Therapeutics
  • RA Capital
  • Ramius Capital Group
  • Ridgeback Capital Management
  • Riverbank Capital
  • Seattle Genetics
  • Shire
  • Singapore BioInnovations
  • Southwest Hospital of the Third Military Medical University, China
  • Stifel
  • Suma Venture
  • Sutro Biopharma
  • Takeda Pharmaceutical
  • Techno Venture Management Capital
  • Texas Children’s Hospital
  • Texas Pacific Group
  • The Scripps Research Institute
  • The University of Texas MD Anderson Cancer Center
  • The Wellcome Trust
  • Third Rock Ventures
  • Transposagen Biopharmaceuticals
  • Triumvira Immunologics
  • University of Munich
  • VenBio
  • Venrock
  • Versant Ventures
  • Wuhan Bio-Raid Biotechnology
  • Yuan Capital

For more information about this report visit

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716